Abstract
Hexarelin is a new hexapeptide (His-d-2-methyl-Trp-Ala-Trp-d-Phe-Lys-NH2) that stimulates the release of growth hormone both in vitro and in vivo. In this double-blind, placebo-controlled, rising-dose study we evaluated the growth hormone releasing activity of hexarelin in healthy human subjects. Twelve adult male volunteers received single intravenous boluses of 0.5, 1 and 2 ·μg·kg−1 hexarelin as well as placebo. For safety, drug doses were given in a rising-dose fashion with placebo randomly inserted into the sequence. Plasma growth hormone concentrations increased dose-dependently after the injection of the peptide, peaking at about 30 min and then decreasing to baseline values within 240 min with a half-life of about 55 min. The mean peak plasma growth hormone concentrations (Cmax) were 3.9, 26.9, 52.3, 55.0 ng·ml−1 after 0, 0.5, 1 and 2 μg·kg−1, respectively. The corresponding areas under the curve of growth hormone plasma levels from drug injection to 180 min (AUC0–180) were 0.135, 1.412, 2.918 and 3.695 μg·min·ml−1. The theoretical maximum response (Emax) and the dose that produces half of the maximum response (ED50) were estimated using logistic regression. The calculated ED50 values were 0.50 and 0.64 μg·kg−1 for Cmax and AUC0–180, respectively. The corresponding Emaxs were 55.1 ng·ml−1 and 3936 ng·min·ml−1, thus indicating that the effect after the 2 μg·kg−1 dose is very close to the maximal response. Plasma glucose, luteinising hormone, follicle-stimulating hormone, thyroid-stimulating hormone and insulin-like growth factor I were unaffected by hexarelin administration, while the peptide caused a slight increase in prolactin, cortisol and adrenocorticotropic hormone levels. Hexarelin was well tolerated in all subjects. The results of this study indicate that intravenous administration of hexarelin in man produces a substantial and dose-dependent increase of growth hormone plasma concentrations.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bowers CY (1993) GH releasing peptides. Structure and kinetics. J Pediatr Endocrinol 6: 21–31
Momany FA, Bowers CY, Reynolds GA, Hong A, Newlander K (1984) Conformational energy studies and in vitro and in vivo activity data on active GH releasing peptides. Endocrinology 114: 1531–1536
Bowers CY, Momany FA, Reynolds GA, Hong A (1984) On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 114: 1537–1545
Bowers CY, Sartor AO, Reynolds GA, Badger TM (1991) On the actions of the growth hormone-releasing hexapeptide, GHRP. Endocrinology 128: 2027–2035
Akman MS, Girard M, O'Brien LF, Ho AR, Chik CL (1993) Mechanisms of action of a second generation growth hormone-releasing peptide (Ala-His-d-βNal-Ala-Trp-d-Phe-Lys-NH2) in rat anterior pituitary cells. Endocrinology 182: 1286–1291
Blake AD, Smith RG (1991) Desensitization studies using-perifused rat pituitary cells show that growth hormone releasing hormone and His-d-Trp-Ala-Trp-d-Phe-Lys-NH2 stimulate growth hormone release through distinct receptor sites. J Endocrinol 129: 11–19
Goth MI, Lyons CE, Canny BJ, Thorner MO (1992) Pituitaryadenylate cyclase activating polypeptide, growth hormone (GH)-releasing peptide and GH-releasing hormone stimulate GH release through distinct pituitary receptors. Endocrinology 130: 939–944
Cheng K, Chan WWS, Barreto A, Convey EM, Smith RG (1989) The synergistic affects of His-d-Trp-Ala-Trp-d-Phe-Lys-NH2 on intracellular adenosine 3′,5′-monophosphate accumulation in rat primary pituitary cell culture. Endocrinology 124: 2791–2798
Codd EE, Shu AY, Walker RF (1989) Binding of a growth hormone releasing hexapeptide to specific hypothalamic and pituitary binding sites. Neuropharmacology 28: 1139–1144
Dickson SL, Leng G, Robinson CAF (1993) Systemic administration of growth hormone-releasing peptide activates hypothalamic arcuate neurons. Neuroscience 53: 303–306
Deghenghi R, Cananzi M, Battisti C, Locatelli V, Müller EE (1992) Hexarelin (EP23905) — a superactive growth hormone releasing peptide. J Endocrinol Invest 15 [Suppl 4]: 45 (A36)
Wehrenberg WB, Giustina A, Imbimbo B, Stagg L, Conley L, Deghenghi R (1992) Biological potency of Hexarelin (EP 23905), a new growth hormone-releasing peptide. J Endocrinol Invest 15 [Suppl 4]: 45 (A37)
Deghenghi R, Cananzi MM, Torsello A, Battisti C, Müller EE, Locatelli V (1994) GH-releasing activity of hexarelin, a new growth hormone releasing peptide, in infant and adult rats. Life Sci 54: 1321–1328
Kuo J, Fox E, McDonald S (1992) SigmaStat. User's Manual. Revision SSD-1.0. Jandel Scientific, Erkrath, Germany
Ilson BE, Jorkasky DK, Curnow RT, Stote RM (1989) Effect of a new synthetic hexapeptide to selectively stimulate growth hormone release in healthy human subjects. J Clin Endocrinol Metab 69: 212–214
Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO (1990) Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab 70: 975–982
Hayashi S, Okimura Y, Yagi H, et al. (1991) Intranasal administration of His-d-Trp-Ala-Trp-d-Phe-Lys-NH2 (growth hormone releasing peptide) increased plasma growth hormone and insuline-like growth factor-I levels in normal men. Endocrinol Jpn 38: 15–21
Bowers CY, Alster DK, Frentz JM (1992) The growth hormone-releasing activity of a synthetic hexapeptide in normal men and short statured children after oral administration. J Clin Endocrinol Metab 74: 292–298
Hartman ML, Farello G, Pezzoli SS, Thorner MO (1992) Oral administration of growth hormone (GH)-releasing peptide stimulates GH secretion in normal men. J Clin Endocrinol Metab 74: 1378–1384
Peñalva A, Pombo M, Carballo A, Barreiro J, Casanueva FF, Dieguez C (1993) Influence of sex, age and adrenergic pathways on the growth hormone response to GHRP-6. Clin Endocrinol 38: 87–91
Bowers CY (1993) Novel GH releasing peptides. Third International Pituitary Congress, Marina del Ray, Calif., 13–15 June. Abstract book: p. S-28
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Imbimbo, B.P., Mant, T., Edwards, M. et al. Growth hormone-releasing activity of hexarelin in humans. Eur J Clin Pharmacol 46, 421–425 (1994). https://doi.org/10.1007/BF00191904
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1007/BF00191904